Mirum president exercises options for 5,912 shares

Mirum Pharmaceuticals president and COO Peter Radovich exercised stock options to acquire 5,912 shares of common stock at an exercise price of $15.87 per share.

Accepted by SEC EDGAR 03/11/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mirum Pharmaceuticals president and COO Peter Radovich exercised stock options to acquire 5,912 shares of common stock at an exercise price of $15.87 per share. These options were fully vested. Following the transaction, he directly owns 26,567 shares of common stock and holds 54,088 stock options.

No shares were sold and no tax-withholding dispositions were reported, making this a straightforward exercise-and-hold transaction that increases his direct equity stake in the company.

Insider Trade Summary

5,912 shares exercised/converted

Exercise 2 txns

Insider Radovich Peter

Role PRESIDENT AND COO

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	5,912	$0.00	$0.00
Exercise	Common Stock	5,912	$15.87	$94K

Holdings After Transaction: Stock Option (right to buy) — 54,088 contracts (Direct); Common Stock — 26,567 shares (Direct)

Footnotes (1)

1. F1. The stock option is fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Mirum Pharmaceuticals (MIRM) report for Peter Radovich?

Mirum Pharmaceuticals reported that president and COO Peter Radovich exercised stock options to acquire 5,912 shares of common stock at $15.87 per share. This transaction increased his direct ownership and involved no open-market share sales or tax-withholding dispositions.

How many Mirum Pharmaceuticals (MIRM) shares does Peter Radovich hold after this Form 4?

After the reported transactions, Peter Radovich directly owns 26,567 shares of Mirum Pharmaceuticals common stock. He also holds 54,088 stock options, reflecting a continued substantial equity position aligned with shareholders through both shares and options exposure.

What was the exercise price of the Mirum Pharmaceuticals (MIRM) options exercised by Peter Radovich?

The exercised Mirum Pharmaceuticals stock options had an exercise, or strike, price of $15.87 per share. Exercising these fully vested options converted 5,912 option rights into the same number of common shares at that fixed price on the transaction date.

Did Mirum Pharmaceuticals (MIRM) executive Peter Radovich sell any shares in this Form 4 filing?

No shares were sold. The Form 4 shows only an exercise of stock options by Peter Radovich to acquire 5,912 common shares. There were no open-market sales or tax-withholding share dispositions associated with this transaction, indicating an exercise-and-hold pattern.

What does the fully vested status of Mirum Pharmaceuticals (MIRM) options mean in this Form 4?

The footnote states the stock option is fully vested, meaning Peter Radovich had already earned the right to exercise all underlying option shares. Vested options can be exercised at the holder’s discretion, converting them into common shares at the predetermined exercise price.

Is the Mirum Pharmaceuticals (MIRM) Form 4 for Peter Radovich primarily a buy or sell signal?

The Form 4 reflects an acquisition via option exercise, not a sale. Peter Radovich exercised options to receive 5,912 shares and retained them, which is typically viewed as a routine compensation-related exercise-and-hold transaction rather than an open-market buy or sell signal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radovich Peter

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND COO

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		M		5,912	A	$15.87	26,567	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$15.87	03/06/2026		M			5,912	(1)	01/05/2032	Common Stock	5,912	$0	54,088	D

Explanation of Responses:

1. The stock option is fully vested.

	/s/ Judit Ryvkin, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.